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OBJECTIVES This study was performed to assess the atrial defibrillation threshold in patients with recurrent
atrial fibrillation (AF) using repeated internal cardioversion.
BACKGROUND Previous studies in patients with chronic AF undergoing internal cardioversion have shown
this method to be effective and safe. However, current energy requirements might preclude
patients with longer-lasting AF from being eligible for an implantable atrial defibrillator.
METHODS Internal shocks were delivered via defibrillation electrodes placed in the right atrium (cathode)
and the coronary sinus (anode) or the right atrium (cathode) and the left pulmonary artery.
After cardioversion, patients were orally treated with sotalol (mean 189 6 63 mg/day). Eighty
consecutive patients with chronic AF (mean duration 291 6 237 days) underwent internal
cardioversion, and sinus rhythm was restored in 74 patients. Eighteen patients underwent
repeated internal cardioversion using the same electrode position and shock configuration
after recurrence of AF (mean duration 34 6 25 days).
RESULTS In these 18 patients, the overall mean defibrillation threshold was 6.67 6 3.09 J for the first
cardioversion and 3.83 6 2.62 J for the second (p 5 0.003). Mean lead impedance was 55.6 6
5.1 V and 57.1 6 3.7 V, respectively (not significant). For sedation, 6.7 6 2.9 mg and 3.9 6
2.2 mg midazolam were administered intravenously (p 5 0.003), and the pain score (0 5 not
felt, 10 5 intolerable) was 5.1 6 1.9 and 2.7 6 1.8 (p 5 0.001). Uni- and multivariate
analyses revealed only the duration of AF before cardioversion to be of relevance, lasting
175 6 113 days before the first and 34 6 25 days before the second cardioversion in these
18 patients (p 5 0.002).
CONCLUSIONS If the duration of AF is reduced, a significant reduction in defibrillation energy requirements
for internal cardioversion ensues. This might extend the group of patients eligible for an
implantable atrial defibrillator despite relatively high initial defibrillation thresholds. (J Am
Coll Cardiol 1999;34:1569–76) © 1999 by the American College of Cardiology
Atrial fibrillation (AF) has been shown to deteriorate
hemodynamics (1–3), to lead to systemic embolism includ-
ing stroke (1,2) and to a twofold risk of cardiac mortality
(1,4). Associated structural changes of the atria foster the
arrhythmia (2). Therefore, prompt restoration of sinus
rhythm is desirable in principle. Several therapeutic options
have been devised for restoration and maintenance of sinus
rhythm, including pharmacological, external and internal
conversion, surgical treatment, atrial pacemaker implanta-
tion, high-frequency ablation of foci and, most recently, an
implantable atrial defibrillator (1,2,5–13). Despite recent
technical advances, such as optimized shock morphology
and electrode position in internal cardioversion (11,14–18),
some concerns still exist with this new mode of treatment.
Relatively high energy requirements (10,16,19–21) and
consequent pain perception (12,17,22–24) currently limit
the use of an automatic atrial defibrillator to patients with
low initial atrial defibrillation thresholds (1,2,5,12,20,25).
Thus, it was the aim of the present study to assess
defibrillation thresholds for repeated internal cardioversion
with respect to patients’ parameters. By proving the hy-
pothesis that shortened AF duration lowers defibrillation
thresholds for internal cardioversion, more patients might
be considered for an implantable atrial defibrillator
(2,16,20,24–26).
METHODS
Patients. In the present study, patients who underwent
repeated internal cardioversion were included. Of 80 pa-
tients to undergo this procedure for chronic AF, sinus
rhythm could be successfully restored in 74, as previously
reported (27).
All 74 patients were on sotalol (189 6 63 mg/day); 35
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had a relapse of AF after a mean follow-up of 14.2 6 6.9
(range 12.5 to 36) months. Eighteen of these patients
requested a second internal cardioversion, and they formed
the basis of this study.
The 18 patients (58 6 6 years of age; 4 women, 14 men,
body weight 75 6 11 kg, body height 170 6 12 cm; left
atrial size 58 6 4 mm) had suffered chronic AF for 175 6
113 days (range 30 to 500 days) before their first cardiover-
sion. The underlying heart disease was diagnosed as coro-
nary artery disease in 5 patients, hypertension in 4, valvular
disease in 4, lone or idiopathic AF in 3 and dilated
cardiomyopathy in 2 patients. Pharmacological conversion
attempts had been performed in 14 patients (72%) before
initial internal cardioversion without success in eight pa-
tients (57%); antiarrhythmic medication did not prevent
recurrent AF in the other six patients.
According to the study protocol (27), approved by the
Ethics Committee of the Technical University of Munich,
patients 21 to 75 years old were enrolled if the following
selection criteria were fulfilled:
1. chronic atrial fibrillation of at least 14 days duration,
documented by serial electrocardiogram (ECG); and
2. effective anticoagulation with warfarin for at least 14 days
(INR [international normalized ratio] 2.5 to 4.2).
Patients were excluded from the study because of:
1. evidence of digitalis toxicity;
2. abnormal electrolyte concentrations;
3. hyperthyroidism;
4. an acute myocardial infarction within the past six weeks;
or
5. a prior history of embolism.
Clinical examination was performed and medical history
was taken. In all patients, routine 12-lead ECG, 24-h
Holter monitoring, chest roentgenogram, routine laboratory
including thyroid parameters and M-mode and Doppler
echocardiography were performed. A transesophageal echo-
cardiography was obtained if clinically indicated. Benefits
and risks of the study were discussed with the patients and
informed consent was obtained.
Protocol for internal cardioversion. The protocol was
carried out as in previous studies (27–29). Two temporary
6 F catheters (Elecath; Electro-Catheter Corp., Rahway,
New Jersey), with an active surface area of 2.62 cm2
consisting of 10 parallel stainless steel rings, were inserted
into the femoral vein and positioned in the right atrium and
either the distal coronary sinus or the left pulmonary artery.
Lead position was randomized: seven patients underwent
cardioversion and had the catheters in the right atrium and
coronary sinus, and 11 patients had the catheters in the right
atrium and pulmonary artery.
Internal cardioversion was performed either in the inten-
sive care unit or in the electrophysiology laboratory. The
patients were sedated orally with 2.5 to 5 mg diazepam.
Immediately before cardioversion, 1 mg midazolam was
administered intravenously; in two anxious patients, 5 mg
midazolam were given. No antiarrhythmic drug was admin-
istered within 48 h before or during the procedure.
The defibrillation threshold was defined as the lowest
shock energy that converted AF into sinus rhythm. Bipha-
sic, two-capacitor shocks of 3 ms/3 ms with phases sepa-
rated by a delay of 0.2 ms were used. The shocks were
delivered by an external defibrillator (Ventritex HVS-02;
Ventritex, Sunnyvale, California) and synchronized to the
R-wave. In order to ensure R-wave synchronization, the
ECG was amplified and filtered by a custom-built, variable-
gain ECG amplifier. Special circuitry prevented shock
delivery when the cycle length was shorter than 500 ms (30).
Oxygen saturation was monitored using a pulse oxymeter,
and the blood pressure was measured every 10 min. Begin-
ning with a test shock of 60-V intensity, the voltage was
increased in 40-V steps until cardioversion was achieved.
Criteria for discontinuation were patient discomfort, com-
plications such as induction of proarrhythmia or major
bleedings, or achieving the maximum voltage of 580 V.
Between unsuccessful defibrillation attempts, at least 1 min
before the next shock was applied. During the study, the
12-lead ECG and intraatrial signals were recorded and
stored (EP Lab, version 6.0; Quinton Electrophysiology,
Inc., Ontario, Canada).
The delivered voltage, current, and morphology for each
shock were recorded using a Macintosh computer and
customized LabVIEW software (National Instruments,
Austin, Texas). The delivered voltage and current wave-
forms were integrated to obtain energy, and impedance was
calculated from the peak voltage and current. Patients were
asked to quantify their level of perceived pain by means of a
scale ranging from 0 (not felt) to 10 (intolerable) after each
shock applied.
Follow-up evaluation. Upon experiencing symptoms sug-
gestive of recurrent AF, patients were asked to return for a
12-lead ECG. Otherwise, follow-ups were performed at 1,
3, 6, 9 and 12 months after cardioversion. All patients were
treated with at least 80 mg bid sotalol (mean daily dose for
these 18 patients 175 6 55 mg, range 160 to 400 mg) after
effective cardioversion to sinus rhythm. Angiotensin con-
verting enzyme inhibitors, diuretics and digitalis were con-
tinued based on the clinical status of the patients. Antico-
agulation was continued after cardioversion and was stopped
only in patients who remained in sinus rhythm for 4 weeks.
Protocol for repeated internal cardioversion. Before the
second internal cardioversion, no patient had an attempt at
Abbreviations and Acronyms
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ECG 5 electrocardiogram
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any other type of conversion. Upon renewed informed
consent, the 18 patients with a mean AF duration of 34 6
25 days (range 7 to 66 days) underwent the same protocol as
for their first cardioversion; the same electrode configuration
was used (Fig. 1). Sotalol was discontinued 48 h before the
procedure. No other antiarrhythmic drugs were given.
Follow-up evaluation after repeated internal cardiover-
sion. On an outpatient basis, a 12-lead ECG was obtained
at 1, 3, 6, 9 and 12 months after cardioversion, or if the
patient had experienced symptoms consistent with recurrent
AF. All patients were treated with at least 80 mg bid sotalol
(mean daily dose 194 6 63 mg, range 160 to 320 mg) after
cardioversion. Angiotensin converting enzyme inhibitors,
diuretics and digitalis were continued based on the clinical
status of the patients. Anticoagulation was stopped in
patients who remained in sinus rhythm confirmed by
12-lead ECG at four weeks.
Statistical analyses. A two-way analysis of variance of the
main effects of both the defibrillation vector (right atrium-
coronary sinus vs. right atrium-left pulmonary artery) and
the defibrillation attempt (first vs. second) was performed. A
uni- and multivariate analysis focused on the influence of
patients’ parameters (age, left atrial diameter, body mass
index, duration of AF and underlying heart disease) on the
defibrillation threshold for internal cardioversion. Continu-
ous variables are expressed as mean 6 standard deviation.
For continuous variables, the Mann Whitney U test for
unpaired groups was used. A predictive value of , 0.05 was
considered to indicate statistical significance.
RESULTS
Short-term efficacy of cardioversion. Of the 80 patients
initially to be treated, internal cardioversion was successful in
74 patients, with a mean defibrillation threshold of 5.81 6 3.20
J. Of the 35 patients who relapsed into AF, 18 patients
underwent repeated internal cardioversion. The initial cardio-
version in these 18 patients was conducted with a mean
defibrillation threshold of 6.67 6 3.09 J, insignificantly higher
compared with the 5.81 6 3.20 J for the 74 patients initially
converted (NS) and to the threshold of 5.22 6 3.32 J for the
39 patients who did not relapse (NS). At the second cardio-
version, energy requirements were 3.83 6 2.62 J and were
approximately 40% lower (p 5 0.003), despite comparable lead
impedance at first and second intervention (55.6 6 5.1 V vs.
57.1 6 3.7 V, NS). In patients using catheters positioned in
the right atrium and the coronary sinus (n 5 7), mean energy
for cardioversion was 4.26 6 1.71 J for the first and 2.83 6
0.86 J for the second (p 5 0.069). With the catheters in the
right atrium and left pulmonary artery (n 5 11), the defibril-
lation threshold was 8.21 6 2.79 and 4.47 6 3.17 J, respec-
tively (p 5 0.011; Table 1). In the first procedure, the
defibrillation threshold for the right atrium-coronary sinus
vector was lower than for the right atrium-pulmonary artery
vector (for the first cardioversion, p 5 0.018; for the second
cardioversion, NS).
Patient characteristics. Of the 18 patients undergoing
repeated internal cardioversion of recurrent AF, body mass
index remained stable throughout the study (26 6
0.8 kg/m2). The mean echocardiographically determined
longitudinal left atrial diameter was 58 6 4 mm (range 53
to 60 mm) at the first and 57 6 3 mm (range 51 to 60 mm)
at the second cardioversion (NS). The duration of atrial
fibrillation (175 6 113 vs. 34 6 25 days, p 5 0.002) was
considerably longer at the time of the first cardioversion
than at the second (Table 1, Fig. 2).
Correlation of defibrillation thresholds and patient pa-
rameters. There was a significant correlation of energy
requirements and duration of AF before the first cardiover-
sion with the right atrium-coronary sinus vector (p 5 0.033,
r2 5 0.629; Fig. 3) and with the right atrium-pulmonary
artery vector (p 5 0.050, r2 5 0.210; Fig. 3). For the second
cardioversion with overall significantly shorter durations, no
such correlation was observed (p 5 0.230, r2 5 0.272 and
p 5 0.668, r2 5 0.004, respectively). There was no corre-
lation between energy requirements and either left atrial size
or body mass index (NS). In terms of symptoms, the pain
Figure 1. Study design for first and second internal cardioversion
of chronic and recurrent AF. Beginning with a test shock of 60-V
intensity, the voltage was increased in 40-V steps until cardiover-
sion was achieved or to a maximum voltage of 580/240 V. The
patients were sedated orally with 2.5 to 5 mg diazepam. Immedi-
ately before cardioversion, 1 mg midazolam was administered
intravenously. Patients were asked to quantify their level of
perceived pain by means of a scale ranging from 0 (5 not felt) to
10 (5 intolerable) after each shock applied.
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scores expressed by patients correlated with defibrillation
thresholds for first and repeated cardioversion for both
vectors (p 5 0.051, r2 5 0.566 and p 5 0.813, r2 5 0.012
for the right atrium-coronary sinus vector vs. p 5 0.014,
r2 5 0.504 and p 5 0.002, r2 5 0.677 for the right
atrium-pulmonary artery vector; Fig. 4).
Uni- and multivariate analysis of patient parameters and
defibrillation threshold. Only the duration of AF before
the first and second cardioversion was significant (p 5
0.0007). Age, body mass index, left atrial diameter and
underlying heart disease were not statistically significant.
Long-term clinical outcome. On an intention-to-treat
basis, 11 of 18 patients successfully treated with repeated
internal cardioversion remained in sinus rhythm after a
mean follow-up of 11.4 6 4 months (range 11 to 18
months; Table 1). In three patients, AF recurred after 7, 14
and 30 days. After their first internal cardioversion, AF had
recurred after 3, 1 and 30 days, respectively. In another three
patients, AF recurred after 3, 14 and 30 days after the first
cardioversion, but 60 days after the second one. One patient
remained in sinus rhythm for 30 days after the first and for
45 days after the second cardioversion.
Complications. There were no complications observed in
the 18 patients of this present study.
DISCUSSION
The present study demonstrates that compared with the
first intervention, despite nearly identical impedance, less
energy is required when internal cardioversion of AF is
performed a second time. In addition, sinus rhythm persists
for a longer period afterwards (Table 1). Furthermore, AF
duration before cardioversion might be a critical parameter,
which is in keeping with the majority of literature reports
available on this issue (2,10,25,31). In this study, a signifi-
cant correlation was seen between defibrillation thresholds
and duration of chronic AF (range from 14 to 500 days) in
patients undergoing internal cardioversion for the first time.
In patients undergoing cardioversion a second time shortly
after the onset of AF (7 to 66 days, mean 34 6 25 days) and
with no other measured patient parameter having changed,
no such correlation is seen. This indicates that in chronic
AF, partially reversible changes over time may lead to
increases in energy requirements.
Influence of AF duration on defibrillation threshold.
These findings do not point to the quality of the electrical
field as the decisive aspect for cardioversion, as has been
noted until recently (1,11,12,14,21,22,24,27,32) but rather
to cellular and subcellular aspects brought about over time
by the arrhythmia itself (2,5,33–36). Atrial atrophy, fibrosis
and dilation are some of the consequences observed in
chronic AF (2), which had been formerly viewed as both its
cause and result (1,2,5,34–36). Apparently, both electrical
changes, such as shortened fibrillatory cycle length and
shortened effective refractory period, and organic lesions, as
already mentioned, impact on the defibrillation threshold.
Electrical phenomena, starting with a shortening of the
atrial refractory period, become full-blown within a few days
Figure 2. Changes in duration of AF (in days), defibrillation thresholds (in J), pain scores (measured by means of a scale ranging from
0 5 not felt to 10 5 intolerable) and dosage of midazolam (in mg) for repeated internal cardioversion (n 5 18): Comparison between first
(open symbols) and second cardioversion (filled symbols) with respect to defibrillation vectors (right atrium-coronary sinus [triangles],
right atrium-pulmonary artery [circles]).
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of chronic AF and can be assumed to be reversible up to one
week after restoration of sinus rhythm (33). With chronic
persistence of AF, however, these phenomena can impinge
on the type of AF (2,33,34) and thus influence its revers-
ibility (10,21,25,27,31,33). By contrast, organic alterations,
such as insulating collagenous septa between atrial muscle
bundles (8), develop over months and years (34), but once
present, they are irreversible, rendering restoration and
maintenance of sinus rhythm more difficult (1,7).
According to both the pathophysiological aspects and the
clinical data of the current study as well as others
(10,22,24,25,31,33), and taking all the possible sequelae of
AF into consideration (1–5), an early cardioversion of AF
should be generally strived for. Comparably low energy
requirements caused by a lower defibrillation threshold after
a comparably short AF duration, and the aim of preventing
occurrences or worsening of the above-mentioned AF-
related phenomena, support this view.
Influence of defibrillation threshold on pain perception.
Recent studies have shown variable response to intracardiac
shocks on pain perception (12,16,20,22,37). In our popula-
tion, there seems to be a strong correlation between energy
applied and pain perceived (Fig. 4). Our previous findings
that energy might determine shock effectiveness but peak
voltage determines pain perception (18) are supported in
this study. Thus, expanding the shock width may afford a
reduction in leading edge voltage, in order to improve
tolerability and to maintain efficacy of internal cardioversion
(18,37).
Influence of defibrillation vector on defibrillation thresh-
old. The selection of the catheter site in the right atrium
and coronary sinus or in the right atrium and left pulmonary
artery determining the shock vector seems to have an effect
on efficacy and on tolerability of internal cardioversion. As
reported previously, the right atrium-coronary sinus vector
requires lower energy thresholds compared with the right
Figure 3. Correlation between duration of AF (in days) before successful internal cardioversion and defibrillation thresholds (in J) for first
(open symbols) and second (filled symbols) cardioversion of AF with respect to defibrillation vectors. (Top) Right atrium-coronary sinus
(triangles). (Bottom) Right atrium-pulmonary artery (circles).
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atrium-pulmonary artery vector (27,38,39). This beneficial
effect on energy implies a favorable effect on tolerability of
internal cardioversion, which can be seen in our group of
patients undergoing cardioversion for the first time (p 5
0.073). In the second cardioversion, a trend favoring the
right atrium-coronary sinus vector can be appreciated (p 5
0.102, NS).
Influence of antiarrhythmic medication on defibrillation
threshold. In order to maintain sinus rhythm, patients
were treated with oral sotalol (mean daily dose 175 6
55 mg, range 160 to 400 mg) based on prior experience
(37,39). In this study, we tried to eliminate the effect of
sotalol on the defibrillation threshold by discontinuing
medication at least 48 h before cardioversion, which equals
four times the elimination half-life of sotalol of 12 h
(40,41). None of the 18 patients had renal insufficiency. So
far, sotalol has been shown to be effective in lowering the
defibrillation threshold in animals (42) and patients with
acute atrial fibrillation (43) only when given concurrently
with a low-energy shock. By contrast to our study, sotalol
was given intravenously (5 mg/kg in canines, 1.5 mg/kg in
humans) and did not reduce the threshold in patients with
chronic AF, but ventricular pacing was required. None of
our 18 patients required ventricular pacing during or after
the cardioversion, consistent with the prior termination of
sotalol medication. However, plasma levels of sotalol were
not obtained.
Clinical implications and conclusions. Initially high de-
fibrillation thresholds could be reduced upon early renewed
shock delivery, presumably due to shorter duration of AF
episodes (24,25). The reported favorable alterations in the
atrial defibrillation threshold for repeated internal cardio-
version could potentially improve the pain perception asso-
ciated with intracardiac shock delivery; consequently, the
number of patients could increase in whom an implantable
device might be considered (2,11,12,18,20,25).
Figure 4. Correlation between defibrillation thresholds (in J) for first (open symbols) and second (filled symbols) internal cardioversion
and pain scores (measured by means of a scale ranging from 0 5 not felt to 10 5 intolerable) at successful internal cardioversion of chronic
and recurrent AF with respect to defibrillation vectors. (Top) Right atrium-coronary sinus (triangles). (Bottom) Right atrium-pulmonary
artery (circles).
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An implantable atrial defibrillator devised for an extended
circle of patients with recurrent AF should incorporate all
qualities required for optimal effectiveness of internal car-
dioversion already mentioned and proper detection of AF in
order to keep episodes of recurrent AF short, thus prevent-
ing electrical remodeling of the atria (1,25).
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